Tempest Therapeutics announced the appointment of Troy M. Wagner as Vice President of Quality Assurance. Prior to Tempest, she was the Vice President of Quality Assurance at Tricida, Inc., where she led all quality assurance functions for manufacturing, testing, holding and distribution activities.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TPST:
- Tempest announces feedback form End-of-Phase 2 meeting with FDA for TPST-1120
- Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
- TPST Upcoming Earnings Report: What to Expect?
- Tempest Therapeutics reports Q2 EPS (42c), consensus (40c)
- Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update